Pull to refresh
Logo
Daily Brief
Following Why
Noninvasive deep brain stimulation advances

Noninvasive deep brain stimulation advances

New Capabilities
By Newzino Staff |

Focused Ultrasound Opens New Windows into the Human Brain

January 12th, 2026: MIT Publishes Consciousness Research Roadmap

Overview

For decades, scientists faced an impossible choice when studying the deep brain: observe from outside with blurry tools, or implant electrodes through surgery. Transcranial magnetic stimulation reaches only 2-4 centimeters below the skull. Functional MRI shows correlation, not causation. Deep brain stimulation requires opening the skull. Now, transcranial focused ultrasound is changing that calculus—sending acoustic waves through intact bone to stimulate regions as small as a few millimeters, deeper and more precisely than any previous noninvasive method.

MIT researchers published a roadmap in January 2026 explaining how this technology could finally let scientists test cause-and-effect in consciousness research. The paper, appearing in Neuroscience and Biobehavioral Reviews, outlines experiments that would modulate specific brain regions—starting with the visual cortex and moving to higher-level areas—while measuring what subjects actually experience. If it works, researchers may finally be able to distinguish between brain activity that generates conscious experience and activity that merely accompanies it.

Key Indicators

25,000+
Patients Treated
Commercial treatments with Insightec's Exablate technology for movement disorders worldwide
1,000x
Precision Improvement
New ultrasound helmets target areas 1,000 times smaller than conventional ultrasound systems
2-4 cm
TMS Depth Limit
Maximum penetration of transcranial magnetic stimulation—focused ultrasound reaches deeper
50%
Tremor Improvement
Reduction in tremor and motor symptoms three months after focused ultrasound treatment for essential tremor

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Sign Up

Debate Arena

Two rounds, two personas, one winner. You set the crossfire.

People Involved

Matthias Michel
Matthias Michel
Associate Professor, MIT Department of Philosophy and Linguistics (Co-author of the consciousness research roadmap)
Daniel Freeman
Daniel Freeman
Technical Staff Member, MIT Lincoln Laboratory (Lead author of the consciousness research roadmap)
William J. Fry
William J. Fry
Pioneer of focused ultrasound (historical) (Deceased)

Organizations Involved

Massachusetts Institute of Technology
Massachusetts Institute of Technology
Research University
Status: Published consciousness research roadmap

MIT researchers developed the roadmap for using transcranial focused ultrasound to study the neural basis of consciousness.

Insightec
Insightec
Medical Device Company
Status: Leading commercial provider of focused ultrasound brain treatment systems

Insightec manufactures the Exablate Neuro system, currently the only FDA-approved focused ultrasound device for treating movement disorders.

Focused Ultrasound Foundation
Focused Ultrasound Foundation
Medical Research Foundation
Status: Funding research and tracking clinical progress

The Focused Ultrasound Foundation funds research and provides resources tracking clinical applications of the technology across neurological, oncological, and other conditions.

NE
NeuroHarmonics
Startup (UCL Spinout)
Status: Developing portable ultrasound brain stimulation devices

NeuroHarmonics is commercializing the UCL-Oxford ultrasound helmet technology as a portable, wearable system.

Timeline

  1. MIT Publishes Consciousness Research Roadmap

    Research

    MIT researchers published a roadmap in Neuroscience and Biobehavioral Reviews explaining how transcranial focused ultrasound could enable causal experiments on consciousness by precisely stimulating deep brain regions while measuring subjective experience.

  2. UCL-Oxford Ultrasound Helmet Unveiled

    Technology

    Researchers from UCL and Oxford announced a 256-element ultrasound helmet that targets brain areas 1,000 times smaller than conventional systems and 30 times smaller than prior deep-brain devices.

  3. Bilateral Parkinson's Treatment Approved

    Regulatory

    FDA approved staged bilateral focused ultrasound treatment for advanced Parkinson's, allowing treatment of both sides of the brain through two separate procedures.

  4. Major Consciousness Theory Test Published

    Research

    Nature published results of adversarial testing between Global Neuronal Workspace and Integrated Information theories of consciousness, finding evidence challenging key tenets of both.

  5. NEJM Publishes Blood-Brain Barrier Opening Results

    Research

    New England Journal of Medicine published results showing focused ultrasound combined with aducanumab reduced amyloid plaques 32% more in targeted brain regions versus untargeted areas in Alzheimer's patients.

  6. Approval for Parkinson's Dyskinesia and Motor Symptoms

    Regulatory

    FDA approved focused ultrasound pallidotomy for Parkinson's-related involuntary movements and motor symptoms.

  7. FDA Approval Extended to Parkinson's Tremor

    Regulatory

    Focused ultrasound received FDA approval for tremor-dominant Parkinson's disease, expanding treatment options beyond essential tremor.

  8. FDA Approves First Noninvasive Focused Ultrasound for Brain

    Regulatory

    The FDA approved Insightec's Exablate Neuro for essential tremor—the first focused ultrasound treatment that works through an intact skull without surgery.

  9. First Focused Ultrasound Brain Surgery

    Clinical Milestone

    Russell Myers and William Fry performed the first successful focused ultrasound brain surgery on a Parkinson's patient at the University of Iowa—a 12-hour procedure requiring craniotomy to bypass the skull.

  10. Clinical Trial of Early Focused Ultrasound

    Research

    Between 1958 and 1962, 88 patients underwent ultrasonic neurosurgery for Parkinson's disease, cerebral palsy, stroke effects, and phantom limb pain.

Scenarios

1

Consciousness Experiments Yield Breakthrough Findings

Discussed by: MIT News, ScienceDaily, neuroscience researchers

Freeman's team successfully conducts the roadmap experiments, starting with the visual cortex and progressing to higher-level regions. Results provide decisive evidence distinguishing activity that generates conscious experience from correlates, advancing resolution of decades-old theoretical debates between cognitivist and sensory-based conceptions of consciousness.

2

Focused Ultrasound Becomes Standard Parkinson's Treatment

Discussed by: Focused Ultrasound Foundation, movement disorder specialists, Insightec

With over 25,000 patients already treated and bilateral treatment now approved, focused ultrasound displaces deep brain stimulation surgery for a majority of medication-refractory Parkinson's patients. Insurance coverage expands, treatment centers proliferate, and the technology becomes first-line for movement disorders within five years.

3

Blood-Brain Barrier Opening Transforms Drug Delivery

Discussed by: New England Journal of Medicine, Alzheimer's researchers, pharmaceutical companies

Building on the 32% improvement in amyloid plaque clearance demonstrated in early trials, focused ultrasound becomes standard adjunct therapy for Alzheimer's treatments. The ability to temporarily open the blood-brain barrier enables previously undeliverable drugs to reach brain targets, expanding treatment options for neurodegenerative diseases.

4

Technical or Safety Limits Constrain Adoption

Discussed by: Clinical researchers, regulatory bodies

Long-term studies reveal unexpected complications or limited efficacy in broader patient populations. The technology remains confined to specialized centers and specific conditions rather than becoming broadly adopted. Consciousness research applications prove harder to implement than the roadmap suggests.

Historical Context

Development of fMRI (1990s)

1990-1992

What Happened

Seiji Ogawa at Bell Labs discovered that blood oxygenation changes could be detected by MRI, and teams at Massachusetts General Hospital and the Medical College of Wisconsin demonstrated the technique could map brain activity. Functional MRI gave researchers their first noninvasive window into the working brain.

Outcome

Short Term

Neuroscience underwent a revolution. Researchers could finally see which brain regions activated during cognitive tasks without surgery.

Long Term

fMRI became the dominant tool in cognitive neuroscience, generating thousands of studies. But it showed correlation only—researchers could see what regions lit up together, not which caused which.

Why It's Relevant Today

Transcranial focused ultrasound addresses fMRI's fundamental limitation: it can manipulate brain activity to establish causation, not just observe correlations. The MIT roadmap explicitly frames ultrasound as the tool to move consciousness research from 'what fires together' to 'what causes what.'

FDA Approval of Deep Brain Stimulation (1997-2002)

1997-2002

What Happened

The FDA approved implanted electrodes for essential tremor in 1997 and Parkinson's disease in 2002. The treatment required neurosurgery to place electrodes deep in the brain connected to a battery pack under the collarbone. Medtronic became the dominant manufacturer.

Outcome

Short Term

Patients who had failed medication found significant symptom relief. The procedure became standard care at major medical centers.

Long Term

More than 200,000 patients received DBS implants over the following two decades. But surgical risks, hardware complications, and cost limited adoption. The average procedure costs $35,000-$100,000.

Why It's Relevant Today

Focused ultrasound offers the precision of deep brain stimulation without surgery. The 2016 FDA approval for essential tremor and subsequent Parkinson's approvals position it as a potential replacement for many DBS candidates, eliminating surgical risks while achieving comparable outcomes.

Transcranial Magnetic Stimulation Clinical Adoption (2008-present)

October 2008

What Happened

The FDA approved TMS for treatment-resistant depression, launching commercial adoption of noninvasive brain stimulation. NeuroStar and other companies built networks of treatment centers. The technique uses magnetic pulses to stimulate cortical neurons.

Outcome

Short Term

TMS became a viable treatment option for depression patients who hadn't responded to medication, with response rates around 50-60% in clinical trials.

Long Term

TMS demonstrated that noninvasive brain stimulation could achieve clinical outcomes. But physical limitations—penetration depth of only 2-4 cm, spatial resolution of 0.5-1 cm—confined its use to surface brain regions.

Why It's Relevant Today

TMS proved the concept of noninvasive therapeutic brain stimulation but hit physical limits. Focused ultrasound achieves what TMS cannot: reaching deep brain structures like the basal ganglia with millimeter precision, opening treatment possibilities for conditions requiring subcortical targeting.

10 Sources:
+4
MIT News ScienceDaily University of Oxford Focused Ultrasound Foundation Insightec New England Journal of Medicine Physics Today Nature PMC Focused Ultrasound Foundation